Arrowhead Pharmaceuticals has clawed back some ground after a brutal month, with the stock up 4.5% on Tuesday to $71.86 — a small but meaningful recovery from the 17% selloff documented last week, and the first sign that sellers may be losing momentum.
The stabilisation in price is mirrored in short positioning. Short interest has effectively flatlined over the past week, edging up less than 0.7% to around 9.67 million shares, or 7.1% of the free float — unchanged from where it was when the previous note flagged the build. The aggressive accumulation that ran from roughly 8.9 million to 9.7 million shares between September 9 and September 16 appears to have stalled. Cost to borrow has actually eased, falling 36% on the week to just 0.37%, its lowest reading in over a month. The lending market remains extremely loose: availability is running at roughly 2,700% of outstanding short interest, meaning there are more than 27 shares available to borrow for every one currently lent out — about as unconstrained as a borrow market gets. The short score sits at 46.9, mid-range and drifting lower over the past two weeks. Taken together, this is a positioning picture where the shorts that built in early September have largely held their ground without meaningfully adding — a pause rather than a retreat.
Options traders are equally calm. The put/call ratio is 0.55, only marginally above its 20-day average of 0.53 and well below the 52-week high of 0.69 hit in mid-August. A z-score of just 0.70 confirms there is no unusual hedging pressure building. Whatever pain was priced in through the September slide, options positioning does not suggest the market is bracing for another leg lower right now.
The Street has not wavered. The consensus remains a firm buy, with nine analysts carrying positive ratings and a mean price target of $110 — implying roughly 53% upside from current levels. Citigroup's initiation of coverage at Buy with a $108 target on September 8 was the most recent new voice, adding institutional weight to a bloc that had already seen Morgan Stanley, Piper Sandler, and HC Wainwright all raise targets in late July following encouraging pipeline data. The bull case centres on plozasiran's commercial trajectory and Arrowhead's breadth across cardiology, liver disease, and pulmonology. Bears point to the continued cash burn — the EV/EBITDA multiple is deeply negative at -17x, and book value trades at over 40x, reflecting a stock priced on future optionality rather than current fundamentals. The analyst recommendation differential factor ranks in the 93rd percentile universe-wide, an unusually strong signal of relative Street enthusiasm.
One ownership dynamic remains worth flagging. Sarepta Therapeutics retains a Schedule 13D activist registration on ARWR — the most recent amendment was filed in August 2025 — with a previously disclosed stake of approximately 9.5% of the class, though the current filing shows no updated share count. Sarepta's holdings also appear in the institutional register at just under 1.9%. The standard caveat applies: 13D positions are disclosed around the 5% threshold and a holder can fall below that level without a further filing. Still, the 13D classification is the most newsworthy fact in the ownership register — it signals stated activist intent, whatever the current holding level. On the insider side, the most recent open-market transactions were discretionary sales by two directors in August at prices around $87, roughly 20% above where the stock trades today. No open-market buying has appeared in the register over the past six months.
With the next earnings event pencilled in for late November, the immediate focus narrows to whether the September short build holds or begins to unwind as the stock recovers, and whether the Sarepta relationship produces any further public disclosures that clarify the activist posture.
See the live data behind this article on ORTEX.
Open ARWR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
